Long term forecasts confirm Keytruda’s dominance
Keytruda sales could be more than double any other product in 2026, new estimates suggests, as Merck’s cancer drug surges into the record books.
Joint makers report pandemic pain
Sales of implants are set to fall sharply as non-urgent procedures are deferred.
New Pfizer, same problem
Pfizer’s chief executive has pledged to throw money at the pharma giant’s thin pipeline and shirk financial engineering, but only canny deal-making will keep investors on…
Mylan gets an injection, administered by Pfizer
The combination of Upjohn and Mylan means that, for a change, Pfizer is getting smaller. But will the company’s new chief executive really be able to resist the urge to…
Indivior fights off generic challenges but the threat of litigation remains
Weaker than expected generic erosion of its key Suboxone film product has allowed Indivior to raise full-year guidance.
Moderna picks its moment
The buttoned-up biotech, recently valued at $7bn, has finally unveiled plans to go public. But investor appetite for new issues has taken a knock. Does Moderna’s move…
Convatec has a poor third quarter for the second year running
An October curse returns to haunt Convatec, and this time it has spooked the CEO.
Abivax seeks funds to follow another fork
Encouraging early data in inflammatory bowel disease have given Abivax a second avenue to pursue with its lead HIV asset.
Could big biotech succumb to the urge to merge?
With growth stalling at some of the industry's biggest biotechs is it time to take a leaf out of big pharma's M&A playbook?
